Danish Medicines Agency launches new concept for National Scientific Advice

31 August 2018

Today, 31 August 2018, the Danish Medicines Agency is launching a new concept for National Scientific Advice for companies, hospitals and others who request advice on the requirements applicable to clinical investigation and marketing authorisations.

On 31 August 2018, the Danish Medicines Agency is launching a new concept for National Scientific Advice for companies, hospitals and others who request advice on the requirements applicable to clinical investigation and marketing authorisations for human and veterinary medicinal products.

The initiative constitutes one of the elements of the Danish government’s Growth Plan for Life Science, and the aim of the initiative is to offer applicants more prioritised and competent National Scientific Advice.

The Agency will offer advice aimed at exploiting already achieved investigational results and on future development programmes. 

Over time, the concept will be expanded to cover other areas such as medical devices, precision medicines and GMP advice.

Payment for Scientific Advice

The new concept will be financed through cost-oriented payment. Thus, payment will vary according to the nature and extent of advice requested by the company/applicant.

Read more about payment and National Scientific Advice

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.